Skip to main content

Advertisement

SpringerLink
Log in

Vitamin D and diabetic nephropathy

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Diabetic nephropathy (DN) is the most common renal complication of diabetes mellitus and a leading cause of end-stage renal disease. The renin-angiotensin system (RAS) is a major mediator of progressive renal injury in DN, and RAS inhibitors have been used as the mainstay treatment for DN. One major problem limiting the efficacy of the RAS inhibitors is the compensatory renin increase caused by disruption of renin feedback inhibition. Vitamin D negatively regulates the RAS by suppressing renin expression and thus plays a renoprotective role in DN. Diabetic vitamin D receptor-null mutant mice develop more severe renal injuries because of more robust RAS activation. Combination therapy with an RAS inhibitor and a vitamin D analogue markedly ameliorates renal injuries due to blockade of the compensatory renin increase by the analogue. These most recent data demonstrate that vitamin D and its analogues have renoprotective and therapeutic potentials in DN through targeting the RAS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Centers for Disease Control and Prevention: National diabetes fact sheet general information and national estimates on diabetes in the United States, 2007. Available at http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf. 2007. Accessed August 28, 2008.

  2. Cooper ME: Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998, 352:213–219.

    Article  PubMed  CAS  Google Scholar 

  3. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813–820.

    Article  PubMed  CAS  Google Scholar 

  4. Carey RM, Siragy HM: The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 2003, 14:274–281.

    Article  PubMed  CAS  Google Scholar 

  5. Ziyadeh FN: Mediators of diabetic renal disease: the case for TGF-beta as the major mediator. J Am Soc Nephrol 2004, 15(Suppl 1):S55–S57.

    Article  PubMed  CAS  Google Scholar 

  6. Furuta T, Saito T, Ootaka T, et al.: The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 1993, 21:480–485.

    PubMed  CAS  Google Scholar 

  7. Lavoie JL, Sigmund CD: Minireview: overview of the reninangiotensin system-an endocrine and paracrine system. Endocrinology 2003, 144:2179–2183.

    Article  PubMed  CAS  Google Scholar 

  8. Paul M, Poyan Mehr A, Kreutz R: Physiology of local renin-angiotensin systems. Physiol Rev 2006, 86:747–803.

    Article  PubMed  CAS  Google Scholar 

  9. Chan JC, Ko GT, Leung DH, et al.: Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000, 57:590–600.

    Article  PubMed  CAS  Google Scholar 

  10. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860.

    Article  PubMed  CAS  Google Scholar 

  11. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878.

    Article  PubMed  CAS  Google Scholar 

  12. Andersen S, Tarnow L, Rossing P, et al.: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000, 57:601–606.

    Article  PubMed  CAS  Google Scholar 

  13. Price DA, Porter LE, Gordon M, et al.: The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999, 10:2382–2391.

    PubMed  CAS  Google Scholar 

  14. Nishiyama A, Seth DM, Navar LG: Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 2002, 39:129–134.

    Article  PubMed  CAS  Google Scholar 

  15. Anderson S, Jung FF, Ingelfinger JR: Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993, 265:F477–F486.

    PubMed  CAS  Google Scholar 

  16. Vidotti DB, Casarini DE, Cristovam PC, et al.: High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol 2004, 286:F1039–F1045.

    Article  PubMed  CAS  Google Scholar 

  17. Yoo TH, Li JJ, Kim JJ, et al.: Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int 2007, 71:1019–1027.

    Article  PubMed  CAS  Google Scholar 

  18. Kelly DJ, Wilkinson-Berka JL, Allen TJ, et al.: A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int 1998, 54:343–352.

    Article  PubMed  CAS  Google Scholar 

  19. Hoffmann S, Podlich D, Hahnel B, et al.: Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol 2004, 15:1475–1487.

    Article  PubMed  CAS  Google Scholar 

  20. Schiffer M, Bitzer M, Roberts IS, et al.: Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001, 108:807–816.

    PubMed  CAS  Google Scholar 

  21. Roestenberg P, van Nieuwenhoven FA, Joles JA, et al.: Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice. Am J Physiol Renal Physiol 2006, 290:F1344–F1354.

    Article  PubMed  CAS  Google Scholar 

  22. Ha H, Yu MR, Choi YJ, et al.: Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol 2002, 13:894–902.

    PubMed  CAS  Google Scholar 

  23. Yamagishi S, Inagaki Y, Okamoto T, et al.: Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002, 277:20309–20315.

    Article  PubMed  CAS  Google Scholar 

  24. Holick MF: Vitamin D: photobiology, metabolism, mechanism of action, and clinical application. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, edn 3. Edited by Favus MJ. Philadelphia: Lippincott-Raven; 1996:74–81.

    Google Scholar 

  25. Haussler MR, Whitfield GK, Haussler CA, et al.: The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998, 13:325–349.

    Article  PubMed  CAS  Google Scholar 

  26. Nagpal S, Na S, Rathnachalam R: Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005, 26:662–687.

    Article  PubMed  CAS  Google Scholar 

  27. Li YC, Qiao G, Uskokovic M, et al.: Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004, 89-90:387–392.

    Article  PubMed  CAS  Google Scholar 

  28. Li YC, Kong J, Wei M, et al.: 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110:229–238.

    PubMed  CAS  Google Scholar 

  29. Zhou CL, Lu FX, Cao KX, et al.: Calcium-independent and 1,25(OH)(2)D(3)-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 2008, 74:170–179.

    Article  PubMed  CAS  Google Scholar 

  30. Xiang W, Kong J, Chen S, et al.: Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005, 288:E125–E132.

    Article  PubMed  CAS  Google Scholar 

  31. Kong J, Qiao G, Zhang Z, et al.: Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int 2008 (in press).

  32. Yuan W, Pan W, Kong J, et al.: 1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007, 282:29821–29830.

    Article  PubMed  CAS  Google Scholar 

  33. Qiao G, Kong J, Uskokovic M, Li YC: Analogs of 1alpha,25-dihydroxyvitamin D3 as novel inhibitors of renin biosynthesis. J Steroid Biochem Mol Biol 2005, 96:59–66.

    Article  PubMed  CAS  Google Scholar 

  34. Fryer RM, Rakestraw PA, Nakane M, et al.: Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron Physiol 2007, 106:p76–p81.

    Article  PubMed  CAS  Google Scholar 

  35. Levin A, Bakris GL, Molitch M, et al.: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007, 71:31–38.

    Article  PubMed  CAS  Google Scholar 

  36. Levin A, Li YC: Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int 2005, 68:1973–1981.

    Article  PubMed  CAS  Google Scholar 

  37. Shoben AB, Rudser KD, de Boer IH, et al.: Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008, 19:1613–1619.

    Article  PubMed  CAS  Google Scholar 

  38. Shoji T, Shinohara K, Kimoto E, et al.: Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004, 19:179–184.

    Article  PubMed  CAS  Google Scholar 

  39. Teng M, Wolf M, Ofsthun MN, et al.: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005, 16:1115–1125.

    Article  PubMed  CAS  Google Scholar 

  40. Kuhlmann A, Haas CS, Gross ML, et al.: 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004, 286:F526–F533.

    Article  PubMed  CAS  Google Scholar 

  41. Makibayashi K, Tatematsu M, Hirata M, et al.: A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 2001, 158:1733–1741.

    PubMed  CAS  Google Scholar 

  42. Zhang Z, Sun L, Wang Y, et al.: Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008, 73:163–171.

    Article  PubMed  CAS  Google Scholar 

  43. Zhang Z, Yuan W, Sun L, et al.: 1,25-Dihydroxyvitamin D(3) targeting of NF-kappaB suppresses high glucoseinduced MCP-1 expression in mesangial cells. Kidney Int 2007, 72:193–201.

    Article  PubMed  CAS  Google Scholar 

  44. Gross JL, de Azevedo MJ, Silveiro SP, et al.: Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28:164–176.

    Article  PubMed  Google Scholar 

  45. Izuhara Y, Nangaku M, Inagi R, et al.: Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005, 16:3631–3641.

    Article  PubMed  CAS  Google Scholar 

  46. Eijkelkamp WB, Zhang Z, Remuzzi G, et al.: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007, 18:1540–1546.

    Article  PubMed  CAS  Google Scholar 

  47. Parving HH, Persson F, Lewis JB, et al.: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433–2446.

    Article  PubMed  CAS  Google Scholar 

  48. Muller DN, Luft FC: Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006, 1:221–228.

    Article  PubMed  Google Scholar 

  49. Li YC: Inhibition of renin: an updated review of the development of renin inhibitors. Curr Opin Investig Drugs 2007, 8:750–757.

    PubMed  CAS  Google Scholar 

  50. Borghi C, Boschi S, Ambrosioni E, et al.: Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993, 33:40–45.

    PubMed  CAS  Google Scholar 

  51. Roig E, Perez-Villa F, Morales M, et al.: Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000, 21:53–57.

    Article  PubMed  CAS  Google Scholar 

  52. Azizi M, Menard J, Bissery A, et al.: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004, 15:3126–3133.

    Article  PubMed  Google Scholar 

  53. Zhang Z, Zhang Y, Ning G, et al.: Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A 2008 (in press).

  54. Shankland SJ: The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006, 69:2131–2147.

    Article  PubMed  CAS  Google Scholar 

  55. Kawachi H, Miyauchi N, Suzuki K, et al.: Role of podocyte slit diaphragm as a filtration barrier. Nephrology (Carlton) 2006, 11:274–281.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, The University of Chicago, MC 4076, 5841 South Maryland Avenue, Chicago, IL, 60637, USA

    Yan Chun Li

Authors
  1. Yan Chun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yan Chun Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, Y.C. Vitamin D and diabetic nephropathy. Curr Diab Rep 8, 464–469 (2008). https://doi.org/10.1007/s11892-008-0080-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-008-0080-4

Keywords

Search

Navigation